Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.4M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
86.1M
-
Shares change
-
+3.34M
-
Total reported value, excl. options
-
$477M
-
Value change
-
+$3.71M
-
Put/Call ratio
-
0.25
-
Number of buys
-
92
-
Number of sells
-
-68
-
Price
-
$5.54
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q4 2024
201 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q4 2024.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.1M shares
of 87.4M outstanding shares and own 98.59% of the company stock.
Largest 10 shareholders include Soleus Capital Management, L.P. (8.14M shares), ORBIMED ADVISORS LLC (7.56M shares), Vivo Capital, LLC (6.9M shares), BlackRock, Inc. (5.74M shares), Deep Track Capital, LP (5.58M shares), Schonfeld Strategic Advisors LLC (4.75M shares), VANGUARD GROUP INC (3.87M shares), MORGAN STANLEY (3.35M shares), CITADEL ADVISORS LLC (3.27M shares), and Nuveen Asset Management, LLC (2.63M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.